58 related articles for article (PubMed ID: 31187861)
1. Efficacy of afatinib treatment for lung adenocarcinoma harboring exon 18 delE709_T710insD mutation.
Iwamoto Y; Ichihara E; Hara N; Nakasuka T; Ando C; Umeno T; Hirabae A; Maeda Y; Kiura K
Jpn J Clin Oncol; 2019 Aug; 49(8):786-788. PubMed ID: 31187861
[TBL] [Abstract][Full Text] [Related]
2. EGFR exon 18 delE709_T710insD mutated stage IV non-small cell lung cancer treated with osimertinib: a case report.
Valcárcel S; Villanueva N; Álvarez C; Esteban E
Anticancer Drugs; 2024 Mar; ():. PubMed ID: 38513159
[TBL] [Abstract][Full Text] [Related]
3. [First-line Treatment with Furmonertinib Mesylate in Lung Adenocarcinoma Patient
with EGFR Exon 20 Insertion Mutantion].
Li Z; Wei T; Zeng D; Zhao L; Zhang J; Chen L
Zhongguo Fei Ai Za Zhi; 2024 Mar; 27(3):241-244. PubMed ID: 38590198
[TBL] [Abstract][Full Text] [Related]
4. Great Efficacy of Afatinib in a Patient with Lung Adenocarcinoma Harboring EGFR L833V/H835L Mutations: A Case Report.
Long X; Qin T; Lin J
Onco Targets Ther; 2020; 13():10689-10692. PubMed ID: 33116645
[TBL] [Abstract][Full Text] [Related]
5. A Lung Adenocarcinoma Patient With a Rare
Wei Y; Cui Y; Guo Y; Li L; Zeng L
Front Oncol; 2021; 11():700345. PubMed ID: 34178699
[TBL] [Abstract][Full Text] [Related]
6. Response to savolitinib in a patient with lung adenocarcinoma harboring a novel MET exon 14 skipping mutation.
Liu Z; Li P; Wu Q; Zhou Q
Asian J Surg; 2024 Apr; 47(4):1851-1852. PubMed ID: 38182507
[No Abstract] [Full Text] [Related]
7. Afatinib treatment of severe respiratory failure due to malignant lymphangitis in a dialysis patient with squamous cell carcinoma of the lung.
Kanai O; Koizumi M; Ito T; Mio T
BMJ Case Rep; 2024 Feb; 17(2):. PubMed ID: 38378591
[TBL] [Abstract][Full Text] [Related]
8. Pneumonic-type lung adenocarcinoma with KRAS G12V mutation and sustained response to Afatinib.
Zhao J; Xu J; Qiu T; Wang J; Wang Z
Pneumonia (Nathan); 2024 Apr; 16(1):7. PubMed ID: 38659041
[TBL] [Abstract][Full Text] [Related]
9. Great efficacy of afatinib on a patient with lung adenocarcinoma harboring uncommon EGFR delE709_T710insD mutations: a case report.
An N; Wang H; Zhu H; Yan W; Jing W; Kong L; Zhang Y; Yu J
Onco Targets Ther; 2019; 12():7399-7404. PubMed ID: 31686847
[TBL] [Abstract][Full Text] [Related]
10. Successful Treatment of a Patient with Lung Adenocarcinoma Harboring Compound EGFR Gene Mutations, G719X and S768I, with Afatinib.
Kutsuzawa N; Takahashi F; Tomomatsu K; Obayashi S; Takeuchi T; Takihara T; Hayama N; Oguma T; Aoki T; Asano K
Tokai J Exp Clin Med; 2020 Sep; 45(3):113-116. PubMed ID: 32901897
[TBL] [Abstract][Full Text] [Related]
11. Afatinib for the Treatment of NSCLC Harboring Uncommon EGFR Mutations: A Database of 693 Cases.
Yang JC; Schuler M; Popat S; Miura S; Heeke S; Park K; Märten A; Kim ES
J Thorac Oncol; 2020 May; 15(5):803-815. PubMed ID: 31931137
[TBL] [Abstract][Full Text] [Related]
12. Potential mechanism of primary resistance to icotinib in patients with advanced non-small cell lung cancer harboring uncommon mutant epidermal growth factor receptor: A multi-center study.
Lei L; Wang WX; Zhu YC; Li JL; Fang Y; Wang H; Zhuang W; Zhang YB; Wang LP; Fang MY; Xu CW; Wang XJ; Lv TF; Song Y
Cancer Sci; 2020 Feb; 111(2):679-686. PubMed ID: 31828849
[TBL] [Abstract][Full Text] [Related]
13. A Rare p.T599dup BRAF Mutant NSCLC in a Non-Smoker.
Turshudzhyan A; Vredenburgh J
Curr Oncol; 2020 Dec; 28(1):196-202. PubMed ID: 33704186
[TBL] [Abstract][Full Text] [Related]
14. ALK rearrangements as mechanisms of acquired resistance to osimertinib in EGFR mutant non-small cell lung cancer.
Hou H; Sun D; Zhang C; Liu D; Zhang X
Thorac Cancer; 2021 Mar; 12(6):962-969. PubMed ID: 33506568
[TBL] [Abstract][Full Text] [Related]
15. A rare EGFR mutation L747P conferred therapeutic efficacy to both gefitinib and osimertinib: A case report.
Huang X; Yang Y; Wang P; Wang J; Chen S; Mao X; Ding L
Lung Cancer; 2020 Dec; 150():9-11. PubMed ID: 33035779
[TBL] [Abstract][Full Text] [Related]
16. Vemurafenib in non-small-cell lung cancer patients with BRAF
Mazieres J; Cropet C; Montané L; Barlesi F; Souquet PJ; Quantin X; Dubos-Arvis C; Otto J; Favier L; Avrillon V; Cadranel J; Moro-Sibilot D; Monnet I; Westeel V; Le Treut J; Brain E; Trédaniel J; Jaffro M; Collot S; Ferretti GR; Tiffon C; Mahier-Ait Oukhatar C; Blay JY
Ann Oncol; 2020 Feb; 31(2):289-294. PubMed ID: 31959346
[TBL] [Abstract][Full Text] [Related]
17. Rare epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer.
Harrison PT; Vyse S; Huang PH
Semin Cancer Biol; 2020 Apr; 61():167-179. PubMed ID: 31562956
[TBL] [Abstract][Full Text] [Related]
18. Afatinib for the Treatment of NSCLC with Uncommon EGFR Mutations: A Narrative Review.
Jiang Y; Fang X; Xiang Y; Fang T; Liu J; Lu K
Curr Oncol; 2023 May; 30(6):5337-5349. PubMed ID: 37366888
[TBL] [Abstract][Full Text] [Related]
19. Response to dacomitinib in advanced non-small-cell lung cancer harboring the rare delE709_T710insD mutation: A case report.
Xu F; Xia ML; Pan HY; Pan JW; Shen YH
World J Clin Cases; 2022 Jun; 10(17):5916-5922. PubMed ID: 35979118
[TBL] [Abstract][Full Text] [Related]
20. Afatinib for the treatment of advanced non-small-cell lung cancer harboring an epidermal growth factor receptor exon 18 E709_T710delinsD mutation: a case report.
Van Acker L; Stevens D; Vermaelen K; Surmont V
J Med Case Rep; 2021 Nov; 15(1):562. PubMed ID: 34809713
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
